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Background
Methotrexate (MTX) is the most widely used disease mod-
ifying anti-rheumatic drug in juvenile idiopathic arthritis
(JIA), inducing long-lasting remission in many patients. It
usually takes 6–12 weeks before anti-inflammatory effects
are clinically noticed, suggesting modulatory effects on T
cells. We examined the effect of MTX on (induced) regula-
tory T cells (Treg) in JIA.
Materials and methods
We sampled 11 patients with active poly-articular JIA
(poly-JIA) prior to and 3–6 months after initiating MTX.
Moreover, 11 poly-JIA patients in remission on MTX were
sampled prior to and 3–6 months after withdrawal of
MTX. Frequency and characteristics of Foxp3+CD4+Treg
and effector T cell subsets were analyzed by flowcytome-
try. Function of Treg was evaluated in suppression assays.
Responses to human heat shock protein 60 (HSP60) were
studied in proliferation assays.
Results
MTX-treatment resulted in a decrease of Foxp3+CD4+ Treg
(3,7% to 2,8% of CD4+T cells). Suppressive function of
Treg was not altered by MTX. Interestingly, stimulation
with anti-CD3 resulted in increased proliferation of
CD4+CD25- effector T cells after 3 months MTX com-
pared to pre-MTX. Moreover, proliferative responses to
human HSP60 increased after MTX-treatment. The quality
of the HSP60-response changed with a less pro-inflamma-
tory cytokine profile in supernatants after MTX-treatment.
When JIA-patients in remission on MTX-treatment with-
drawed MTX, the frequency of Treg increased (3,2 to 3,8%
of CD4+ T cells) but their suppressive function remained
unchanged.
Conclusion
MTX seems to exert its immune-modulating effects not by
affecting Foxp3+ Treg. Instead, we observed changes in
effector T cells and HSP60 specific T cells.
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